CPAP, weight loss, or both for obstructive sleep apnea.

Area of Science:

• Cardiology
• Pulmonology
• Metabolic Disorders

Background:

• Obesity and obstructive sleep apnea (OSA) frequently coexist, contributing to inflammation, insulin resistance, dyslipidemia, and hypertension.
• The precise causal links between obesity, OSA, and these metabolic abnormalities remain incompletely understood.

Purpose of the Study:

• To investigate the incremental effects of continuous positive airway pressure (CPAP) and weight-loss interventions, alone and in combination, on C-reactive protein (CRP) levels, insulin sensitivity, lipid profiles, and blood pressure in patients with obesity and moderate-to-severe OSA.

Main Methods:

• A randomized controlled trial involving 181 patients with obesity, moderate-to-severe OSA, and elevated CRP levels.
• Participants were assigned to CPAP, weight-loss intervention, or a combination of both for 24 weeks.
• Primary endpoint was the change in CRP levels; secondary endpoints included changes in insulin sensitivity, lipids, and blood pressure.

Main Results:

• Weight loss interventions (alone or combined with CPAP) significantly reduced CRP levels, insulin resistance, and triglyceride levels.
• CPAP alone did not yield these improvements.
• Combined interventions showed greater reductions in insulin resistance and triglycerides compared to CPAP alone, but not compared to weight loss alone.
• Blood pressure decreased across all groups, with greater reductions in systolic and mean arterial pressure observed with combined interventions in per-protocol analyses.

Conclusions:

• Combining CPAP with weight loss does not offer superior CRP reduction compared to individual interventions in obese patients with OSA.
• Weight loss provides incremental benefits for insulin resistance and triglyceride levels when used with CPAP.
• Adherent combined therapy may lead to enhanced blood pressure reduction compared to monotherapy.